NCT01418222

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 194 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	5-FU	Intravenous repeating dose
DRUG	FOLFOX regimen	Intravenous repeating dose
DRUG	Placebo	Intravenous repeating dose
DRUG	bevacizumab [Avastin]	Intravenous repeating dose
DRUG	leucovorin	Intravenous repeating dose
DRUG	onartuzumab [MetMAb]	Intravenous repeating dose

Timeline

• Start date: 2011-09-14
• Primary completion: 2013-03-18
• Completion: 2013-03-18
• First posted: 2011-08-17
• Last updated: 2017-05-30

Locations

23 sites across 1 country: United States